Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9803
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFoo, Serene Sen
dc.contributor.authorAbbott, David Fen
dc.contributor.authorLawrentschuk, Nathanen
dc.contributor.authorScott, Andrew Men
dc.date.accessioned2015-05-15T23:03:04Z
dc.date.available2015-05-15T23:03:04Z
dc.date.issued2004-09-10en
dc.identifier.citationMolecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging; 6(5): 291-305en
dc.identifier.govdoc15380739en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9803en
dc.description.abstractTumor hypoxia plays a fundamental role in tumor progression and treatment resistance. Recent evidence that hypoxia also influences the regulation and transcription of various genes involved in malignant growth and metastases, and promotes a more aggressive tumor phenotype makes its diagnosis even more important.The evidence for the biology of hypoxia in tumors, and imaging of hypoxia with different technologies was reviewed through literature review and Medline searches, and clinical studies with 18F-fluoromisonidazole (FMISO) Positron Emission Tomography (PET).Until recently, determination of the level of tumor oxygenation was only possible using invasive methods that limited its clinical application. Imaging techniques that have shown promise in assessing hypoxia include magnetic resonance imaging and spectroscopy, single photon emission computed tomography (SPECT) and PET. Quantitative hypoxia measurement with 18F-FMISO PET in patients with malignant gliomas and lung cancer have demonstrated intratumoural hypoxia and dissociation of glucose metabolism from hypoxia in some cases, indicating the complex nature of cellular metabolic response to stress.The emerging role of therapies that have improved efficacy in hypoxic conditions, and recent advances in the ability to noninvasively measure in vivo intratumoral hypoxia with functional imaging has renewed interest in the clinical measurement of tumor hypoxia and its impact on cancer treatment.en
dc.language.isoenen
dc.subject.otherAnoxia.metabolismen
dc.subject.otherCell Hypoxiaen
dc.subject.otherElectron Spin Resonance Spectroscopy.trendsen
dc.subject.otherForecastingen
dc.subject.otherHumansen
dc.subject.otherMagnetic Resonance Spectroscopyen
dc.subject.otherNeoplasms.metabolism.radiographyen
dc.subject.otherPositron-Emission Tomography.trendsen
dc.subject.otherTomography, Emission-Computed, Single-Photon.trendsen
dc.titleFunctional imaging of intratumoral hypoxia.en
dc.typeJournal Articleen
dc.identifier.journaltitleMolecular imaging and biology : MIB : the official publication of the Academy of Molecular Imagingen
dc.identifier.affiliationLudwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Victoria, Australiaen
dc.identifier.doi10.1016/j.mibio.2004.06.007en
dc.description.pages291-305en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15380739en
dc.type.austinJournal Articleen
local.name.researcherAbbott, David F
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Nov 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.